Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
22.82
+0.88 (4.01%)
Oct 19, 2026, 4:00 PM EDT - Market closed
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
895.50M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| Rigel Pharmaceuticals | 276.79M |
| Arbutus Biopharma | 181.72M |
| Monte Rosa Therapeutics | 28.73M |
| Aktis Oncology | 10.06M |
| SL Science Holding | 3.27M |
| Odyssey Therapeutics | 99.00K |
ANRO News
- 15 hours ago - Alto Neuroscience price target raised to $60 from $55 at H.C. Wainwright - TheFly
- 19 days ago - Alto Neuroscience Slides: Investor presentation - Filings
- 26 days ago - Alto Neuroscience Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - Transcripts
- 5 weeks ago - Alto Neuroscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Alto Neuroscience names Nick Smith president, CFO - TheFly
- 7 weeks ago - Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer - Business Wire
- 2 months ago - Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright - TheFly